Charting a Proven Path in Neuroscience.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation.
Description
Puretech Ownership1
Stage of Development
Lorem ipsum dolor sit amet, consectetur adipiscingLorem ipsum dolor sit amet, consectetur adipiscing
100% Equity
Phase 2
Description
Lorem ipsum dolor sit amet, consectetur adipiscingLorem ipsum dolor sit amet, consectetur adipiscing
Puretech Ownership1
100% Equity
Stage of Development
Phase 2
The FDA and corresponding regulatory authorities will ultimately review our clinical results and determine whether our wholly-owned therapeutic candidates are safe and effective. No regulatory agency has made any such determination that our wholly-owned therapeutic candidates are safe or effective for use by the general public for any indication.
Initial Indications
Neuropsychiatric and rare CNS conditions
Key Differentiation
Designed to overcome the poor oral bioavailability of allopregnanolone to advance what we believe could be a best-in-class new medicine for treating anxiety, mood disorders and Fragile X-associated Tremor/ Ataxia Syndrome. Allopregnanolone is a positive allosteric modulator of GABAA receptors that has therapeutic potential across a wide range of neurological conditions, including anxiety and Fragile X-associated Tremor/ Ataxia Syndrome, ...
Initial Indications
Epilepsies & other neurological indications
Key Differentiation
Therapeutic candidate designed to unlock the validated efficacy of cannabidiol (CBD). Derived from the Glyph platform, LYT-310 offers oral dosing and the potential for improved tolerability, which could expand the therapeutic application of CBD across a wider range of age groups and indications, including both rare and more common forms of epilepsy and other neurological indications.
Initial Indications
Anxiety and mood disorders
Key Differentiation
A novel prodrug of agomelatine that is designed to allow for bypass of first-pass metabolism by the liver, and thus has the potential to reduce liver exposure, hepatotoxicity, and the need for liver function monitoring.
Key Differentiation
Glyph is our lymphatic-targeting platform which is designed to employ the lymphatic system's natural lipid absorption and transport process to enable the oral administration of certain therapeutics. Glyph reversibly links a drug to a dietary fat molecule, creating a novel prodrug. The linked fat molecule re-routes the drug's normal path to the systemic circulation, bypassing the liver and instead moving from the gut into the lymphatic vessels that normally process dietary fats.